Clinical trials sponsored by Jiangsu Cancer Institute & Hospital

Phase breakdown

Conditions studied

Recruiting trials led by Jiangsu Cancer Institute & Hospital

• A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
  NCT07082179 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
  NCT06198868 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
  NCT07601178 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Jiangsu Cancer Institute & Hospital recruiting for?

Jiangsu Cancer Institute & Hospital is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.